RecruitingPhase 2NCT07630727

Study of AHB-171 in Chronic Hepatitis B Participants

An Open-label Phase II Clinical Study to Evaluate the Efficacy and Safety of AHB-171 Injection in Participants With Chronic Hepatitis B

Sponsor

Ausper Biopharma Co., Ltd.

Enrollment

138 participants

Start Date

Jun 24, 2026

Study Type

INTERVENTIONAL

Conditions

Hepatitis B, Chronic (CHB)

Summary

The study adopts an open-label, multiple-dose design and aims to evaluate the efficacy and safety of AHB-171 Injection after multiple doses in treatment-naïve (HBeAg-negative/positive) and nucleos(t)ide analogue (NA)-treated (HBeAg-negative) participants with chronic hepatitis B (CHB)

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called AHB-171 Injection for people with hepatitis b, chronic (chb). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.